Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QR-440
- Development stage
- Unknown
- Lead developer
- Quigley Pharma
- Modality
- Small Molecules
01
Overview
QR-440 is a veterinary drug candidate that was under development by Quigley Pharma, a subsidiary of The Quigley Corporation (now ProPhase Labs). Described as a naturally derived compound, it was intended for the treatment of various inflammatory conditions in animals and received an Investigational New Animal Drug (INAD) number from the FDA's Center for Veterinary Medicine. Preclinical data suggested that the compound possessed both anti-inflammatory and potential disease-modifying properties, distinguishing it from standard palliative treatments. Development of QR-440 appears to have been discontinued following the parent company's restructuring and transition into ProPhase Labs around 2009.
Beyond the preview
Go deeper on QR-440.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QR-440.